SuspendedPHASE1, PHASE2NCT01512888
Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
Studying T-B+ severe combined immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Jude Children's Research Hospital
- Principal Investigator
- Stephen Gottschalk, MD, MDSt. Jude Children's Research Hospital
- Intervention
- CL20-i4-EF1α-hγc-OPT(genetic)
- Enrollment
- 28 enrolled
- Eligibility
- MALE
- Timeline
- 2016 – 2034
Study locations (3)
- University of California-San Francisco, San Francisco, California, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- Seattle Children's Research Institute, Seattle, Washington, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI) · Assisi Foundation · California Institute for Regenerative Medicine (CIRM)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01512888 on ClinicalTrials.govOther trials for T-B+ severe combined immunodeficiency
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06851767Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE2NCT03619551Conditioning SCID Infants Diagnosed EarlyCenter for International Blood and Marrow Transplant Research
- RECRUITINGPHASE1, PHASE2NCT01306019Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)National Institute of Allergy and Infectious Diseases (NIAID)